296 related articles for article (PubMed ID: 18178863)
21. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
22. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.
Knight JS; Subramanian V; O'Dell AA; Yalavarthi S; Zhao W; Smith CK; Hodgin JB; Thompson PR; Kaplan MJ
Ann Rheum Dis; 2015 Dec; 74(12):2199-206. PubMed ID: 25104775
[TBL] [Abstract][Full Text] [Related]
23. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
24. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE.
Boackle SA; Culhane KK; Brown JM; Haas M; Bao L; Quigg RJ; Holers VM
Autoimmunity; 2004 Mar; 37(2):111-23. PubMed ID: 15293881
[TBL] [Abstract][Full Text] [Related]
25. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
26. Iron status alters murine systemic lupus erythematosus.
Leiter LM; Reuhl KR; Racis SP; Sherman AR
J Nutr; 1995 Mar; 125(3):474-84. PubMed ID: 7876923
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of BET protein BRD4 delays murine lupus.
Wei S; Sun Y; Sha H
Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
[TBL] [Abstract][Full Text] [Related]
28. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in Murine Lupus Nephritis.
Gonzalo-Gil E; García-Herrero C; Toldos O; Usategui A; Criado G; Pérez-Yagüe S; Barber DF; Pablos JL; Galindo M
Front Immunol; 2018; 9():1948. PubMed ID: 30210500
[No Abstract] [Full Text] [Related]
29. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
30. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
31. Anti-C1q autoantibodies in murine lupus nephritis.
Trouw LA; Seelen MA; Visseren R; Duijs JM; Benediktsson H; de Heer E; Roos A; van Kooten C; Daha MR
Clin Exp Immunol; 2004 Jan; 135(1):41-8. PubMed ID: 14678263
[TBL] [Abstract][Full Text] [Related]
32. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
Liang B; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 2000 Sep; 165(6):3436-43. PubMed ID: 10975864
[TBL] [Abstract][Full Text] [Related]
33. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
Chalmers SA; Wen J; Shum J; Doerner J; Herlitz L; Putterman C
Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice.
Zhao C; Gu Y; Chen L; Su X
Int Immunopharmacol; 2020 Dec; 89(Pt A):107027. PubMed ID: 33039957
[TBL] [Abstract][Full Text] [Related]
35. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
36. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.
Alexander JJ; Jacob A; Bao L; Macdonald RL; Quigg RJ
J Immunol; 2005 Dec; 175(12):8312-9. PubMed ID: 16339572
[TBL] [Abstract][Full Text] [Related]
37. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Shi Y; Yao W; Sun L; Li G; Liu H; Ding P; Hu W; Xu H
BMC Nephrol; 2019 Nov; 20(1):424. PubMed ID: 31752725
[TBL] [Abstract][Full Text] [Related]
38. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.
Miwa T; Maldonado MA; Zhou L; Yamada K; Gilkeson GS; Eisenberg RA; Song WC
Am J Pathol; 2007 Apr; 170(4):1258-66. PubMed ID: 17392165
[TBL] [Abstract][Full Text] [Related]
39. Absence of functional alternative complement pathway alleviates lupus cerebritis.
Alexander JJ; Jacob A; Vezina P; Sekine H; Gilkeson GS; Quigg RJ
Eur J Immunol; 2007 Jun; 37(6):1691-701. PubMed ID: 17523212
[TBL] [Abstract][Full Text] [Related]
40. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
Front Immunol; 2020; 11():1047. PubMed ID: 32625200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
